[177Lu]Lu-DPI-4452

DRUG2 trials

Conditions

Clear Cell Renal Cell Cancer (ccRCC)Colorectal Cancer (CRC)Head and Neck Cancer (H&N)Indeterminate Renal Mass (IDRM)Muscle Invasive Bladder Cancer (MIBC)Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Non-Small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer (TNBC)

Phase 1

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

RecruitingNCT05706129

Lumara Bio Oncologics GmbHClear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer (CRC), Head and Neck Cancer (H&N) +6

Start: 2023-03-14End: 2029-03-01Target: 270Updated: 2026-08-11

A multicenter, open-label, non-randomized Phase 1/2 study to assess safety, tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors

RecruitingCTIS2023-504254-35-00

ITM Oncologics GmbHUnresectable locally advanced or metastatic solid tumors: • Clear cell renal cell carcinoma (ccRCC) • Pancreatic ductal adenocarcinoma (PDAC) • Colorectal Cancer (CRC) (Part A) • Urothelial carcinoma (UC) [Part B/C/E] • Indeterminate Renal Mass (IDRM) [part D] • Head and Neck cancer (H&N) [part E] • Triple Negative breast cancer (TNBC) [part E] • Squamous non-mall cell lung cancer (NSCLC) [part E]

Start: 2023-06-20Target: 97Updated: 2026-01-09

Journal of Clinical Oncology2024-01-291 citations

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.

Journal of Clinical Oncology2023-06-013 citations

[177Lu]Lu-DPI-4452

Sponsors

Conditions

Phase 1

Related Papers